A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
about
The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?Efavirenz and the CNS: what we already know and questions that need to be answeredClinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected populationEfavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.Neurological and psychiatric adverse effects of antiretroviral drugs.Neuropsychiatric Effects of HIV Antiviral Medications.Representation of women and pregnant women in HIV research: a limited systematic review.Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Prevalence and factors associated with sleep disturbances among early-treated HIV-infected personsModifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.Does once-daily etravirine have a role in the management of HIV-1 infection?Switch strategies in antiretroviral therapy regimens.Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.Interventions for Neurocognitive Dysfunction.Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.Does efavirenz replacement improve neurological function in treated HIV infection?Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs.Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q27030892-CA33C772-1581-4FE2-96A8-318A90B44DD3Q28085028-D0C6112A-CFB2-4653-9B45-6D3CB76C0DE2Q28538921-55279A8B-1676-4FDF-9973-9B52C80913F0Q31159582-511B7C51-B05D-487E-AE05-E00F637439FEQ33413634-F9C8197E-40CF-446C-AD81-CB9B328266E6Q34039419-EF68997C-9BFF-4955-92A6-93B556D40227Q34537705-1E2B77A1-39D6-474B-BD24-394DCAAA2F6CQ34979789-9D4C9769-3356-4719-A08C-EF3A196F1BFEQ35087745-B04861D5-744C-4A3C-AEAA-892FA064BB57Q35147189-5C1B43CF-DF62-4008-95FA-46610221C38CQ35906888-4833D60F-F9A0-4D3B-A941-3B008D1314FDQ36426953-5F3109C0-856F-4DD4-B364-91D3A6909A33Q36634843-95D097F7-E411-450D-8BAD-473681140524Q37077340-38799053-06CC-40CE-A270-9FD266342473Q37639881-9067D8DB-57B6-404E-A667-AB53A57266A7Q37722935-F9C15970-9C21-415C-A755-E1E757F416EAQ38082671-F36F6589-0ADA-43E8-864E-37E7C0475C33Q38235295-4553E969-0795-4BA4-BF69-01300BF6511BQ38723259-2D16586E-583A-4D16-BB84-C7850A28AAFAQ38767396-73D0B876-EA23-44C7-B2CC-4FAE95DB8E64Q38813848-A5537FE5-49C7-4EDD-A328-9937F8E373E8Q39344476-3A71D779-2FC8-403B-9327-FA716BA15A49Q40143100-BAC3C5E8-5CBD-4556-99F9-2AB6F424B2ABQ41059063-55E033F9-18E6-4A8C-863E-D78742226AC4Q42241221-F4F88BA6-A16C-45C3-BABD-222196F920DBQ42276735-74A97393-D051-43D7-83DD-F38A3C640CF8Q42592784-9912F22A-C4BE-424B-86E3-C28B9410BFDFQ47567926-67D3C1D2-2BCC-42E9-A058-68DF11A75F31Q57180790-EFEFC036-625F-40B9-A4AA-A51716FFFDD8
P2860
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase IV, double-blind, mult ...... adverse events to etravirine.
@ast
A phase IV, double-blind, mult ...... adverse events to etravirine.
@en
type
label
A phase IV, double-blind, mult ...... adverse events to etravirine.
@ast
A phase IV, double-blind, mult ...... adverse events to etravirine.
@en
prefLabel
A phase IV, double-blind, mult ...... adverse events to etravirine.
@ast
A phase IV, double-blind, mult ...... adverse events to etravirine.
@en
P2093
P1433
P1476
A phase IV, double-blind, mult ...... adverse events to etravirine.
@en
P2093
Alan Winston
Chris Higgs
Laura Waters
Lucy Garvey
Mackie Nicola
Mark Nelson
Martin Fisher
Nicky Perry
Sundhiya Mandalia
Wendy Hadley
P356
10.1097/QAD.0B013E328341685B
P407
P577
2011-01-01T00:00:00Z